R
Rossella Barni
Publications - 4
Citations - 923
Rossella Barni is an academic researcher. The author has contributed to research in topics: ABL & breakpoint cluster region. The author has an hindex of 4, co-authored 4 publications receiving 916 citations.
Papers
More filters
Journal ArticleDOI
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.
Philipp le Coutre,Elena Tassi,Marileila Varella-Garcia,Rossella Barni,Luca Mologni,Gonçalo Cabrita,Edoardo Marchesi,Rosanna Supino,Carlo Gambacorti-Passerini +8 more
TL;DR: Overexpression of the Bcr/Abl protein mediated through gene amplification is associated with and probably determines resistance of human leukemic cells to STI571 in vitro.
Journal ArticleDOI
Role of α1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571
Carlo Gambacorti-Passerini,Rossella Barni,Philipp le Coutre,Massimo Zucchetti,Gonçalo Cabrita,Loredana Cleris,Francesca Rossi,Elisabetta Gianazza,Josef Brueggen,Robert Cozens,Pietro Pioltelli,Enrico Pogliani,Gianmarco Corneo,Franca Formelli,Maurizio D'Incalci +14 more
TL;DR: AGP in the plasma of relapsed animals binds to STI571, preventing this compound from inhibiting the Bcr/Abl tyrosine kinase, and molecules such as erythromycin that compete with STi571 for binding to AGP may enhance the therapeutic potential of this drug.
Journal ArticleDOI
Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease.
Carlo Gambacorti-Passerini,Rossella Barni,Edoardo Marchesi,Magda Verga,Francesca Rossi,Fabio Rossi,Pietro Pioltelli,Enrico Pogliani,Gian Marco Corneo +8 more
TL;DR: Leukaemic cells from six CML patients from whom samples could be obtained during chronic phase and at the time of blast crisis (BC) were compared for sensitivity to STI571, using an in vitro assay, suggesting that no substantial intrinsic resistance to STi571 was present in BC.
Journal Article
Differential Recognition of a BCR/ABL Peptide by Lymphocytes from Normal Donors and Chronic Myeloid Leukemia Patients
Carla Bertazzoli,Edoardo Marchesi,Lorena Passoni,Rossella Barni,Fernando Ravagnani,Claudia Lombardo,Gian Marco Corneo,Pietro Pioltelli,Enrico Pogliani,Carlo Gambacorti-Passerini +9 more
TL;DR: The data suggest that immunocompetent, HLA-DR0401+ CML patients are unable to respond to peptide B/A1, at difference from healthy donors, thus excluding the presence of generalized immunosuppression.